Single-incision sling operations for urinary incontinence in women.
Journal
The Cochrane database of systematic reviews
ISSN: 1469-493X
Titre abrégé: Cochrane Database Syst Rev
Pays: England
ID NLM: 100909747
Informations de publication
Date de publication:
27 10 2023
27 10 2023
Historique:
pmc-release:
27
10
2024
medline:
30
10
2023
pubmed:
27
10
2023
entrez:
27
10
2023
Statut:
epublish
Résumé
Stress urinary incontinence imposes a significant health and economic burden on individuals and society. Single-incision slings are a minimally-invasive treatment option for stress urinary incontinence. They involve passing a short synthetic device through the anterior vaginal wall to support the mid-urethra. The use of polypropylene mesh in urogynaecology, including mid-urethral slings, is restricted in many countries. This is a review update (previous search date 2012). To assess the effects of single-incision sling operations for treating urinary incontinence in women, and to summarise the principal findings of relevant economic evaluations. We searched the Cochrane Incontinence Specialised Register, which contains trials identified from: CENTRAL, MEDLINE, MEDLINE In-Process, MEDLINE Epub Ahead of Print, and two trials registers. We handsearched journals, conference proceedings, and reference lists of relevant articles to 20 September 2022. We included randomised or quasi-randomised controlled trials in women with stress (or stress-predominant mixed) urinary incontinence in which at least one, but not all, trial arms included a single-incision sling. We used standard Cochrane methodological procedures. The primary outcome was subjective cure or improvement of urinary incontinence. We included 62 studies with a total of 8051 women in this review. We did not identify any studies comparing single-incision slings to no treatment, conservative treatment, colposuspension, or laparoscopic procedures. We assessed most studies as being at low or unclear risk of bias, with five studies at high risk of bias for outcome assessment. Sixteen trials used TVT-Secur, a single-incision sling withdrawn from the market in 2013. The primary analysis in this review excludes trials using TVT-Secur. We report separate analyses for these trials, which did not substantially alter the effect estimates. We identified two cost-effectiveness analyses and one cost-minimisation analysis. Single-incision sling versus autologous fascial sling One study (70 women) compared single-incision slings to autologous fascial slings. It is uncertain if single-incision slings have any effect on risk of dyspareunia (painful sex) or mesh exposure, extrusion or erosion compared with autologous fascial slings. Subjective cure or improvement of urinary incontinence at 12 months, patient-reported pain at 24 months or longer, number of women with urinary retention, quality of life at 12 months and the number of women requiring repeat continence surgery or sling revision were not reported for this comparison. Single-incision sling versus retropubic sling Ten studies compared single-incision slings to retropubic slings. There may be little to no difference between single-incision slings and retropubic slings in subjective cure or improvement of incontinence at 12 months (risk ratio (RR) 0.99, 95% confidence interval (CI) 0.91 to 1.07; 2 trials, 297 women; low-certainty evidence). It is uncertain whether single-incision slings increase the risk of mesh exposure, extrusion or erosion compared with retropubic minimally-invasive slings; the wide confidence interval is consistent with both benefit and harm (RR 1.55, 95% CI 0.24 to 9.82; 3 trials, 267 women; low-certainty evidence). It is uncertain whether single-incision slings lead to fewer women having postoperative urinary retention compared with retropubic slings; the wide confidence interval is consistent with possible benefit and harm (RR 0.47, 95% CI 0.12 to 1.84; 2 trials, 209 women; low-certainty evidence). The effect of single-incision slings on the risk of repeat continence surgery or mesh revision compared with retropubic slings is uncertain (RR 4.19, 95% CI 0.31 to 57.28; 2 trials, 182 women; very low-certainty evidence). One study reported quality of life, but not in a suitable format for analysis. Patient-reported pain at more than 24 months and the number of women with dyspareunia were not reported for this comparison. We downgraded the evidence due to concerns about risks of bias, imprecision and inconsistency. Single-incision sling versus transobturator sling Fifty-one studies compared single-incision slings to transobturator slings. The evidence ranged from high to low certainty. There is no evidence of a difference in subjective cure or improvement of incontinence at 12 months when comparing single-incision slings with transobturator slings (RR 1.00, 95% CI 0.97 to 1.03; 17 trials, 2359 women; high-certainty evidence). Single-incision slings probably have a reduced risk of patient-reported pain at 24 months post-surgery compared with transobturator slings (RR 0.12, 95% CI 0.02 to 0.68; 2 trials, 250 women; moderate-certainty evidence). The effect of single-incision slings on the risk of dyspareunia is uncertain compared with transobturator slings, as the wide confidence interval is consistent with possible benefit and possible harm (RR 0.78, 95% CI 0.41 to 1.48; 8 trials, 810 women; moderate-certainty evidence). There are a similar number of mesh exposures, extrusions or erosions with single-incision slings compared with transobturator slings (RR 0.61, 95% CI 0.39 to 0.96; 16 trials, 2378 women; high-certainty evidence). Single-incision slings probably result in similar or reduced cases of postoperative urinary retention compared with transobturator slings (RR 0.68, 95% CI 0.47 to 0.97; 23 trials, 2891 women; moderate-certainty evidence). Women with single-incision slings may have lower quality of life at 12 months compared to transobturator slings (standardised mean difference (SMD) 0.24, 95% CI 0.09 to 0.39; 8 trials, 698 women; low-certainty evidence). It is unclear whether single-incision slings lead to slightly more women requiring repeat continence surgery or mesh revision compared with transobturator slings (95% CI consistent with possible benefit and harm; RR 1.42, 95% CI 0.94 to 2.16; 13 trials, 1460 women; low-certainty evidence). We downgraded the evidence due to indirectness, imprecision and risks of bias. Single-incision sling operations have been extensively researched in randomised controlled trials. They may be as effective as retropubic slings and are as effective as transobturator slings for subjective cure or improvement of stress urinary incontinence at 12 months. It is uncertain if single-incision slings lead to better or worse rates of subjective cure or improvement compared with autologous fascial slings. There are still uncertainties regarding adverse events and longer-term outcomes. Therefore, longer-term data are needed to clarify the safety and long-term effectiveness of single-incision slings compared to other mid-urethral slings.
Sections du résumé
BACKGROUND
Stress urinary incontinence imposes a significant health and economic burden on individuals and society. Single-incision slings are a minimally-invasive treatment option for stress urinary incontinence. They involve passing a short synthetic device through the anterior vaginal wall to support the mid-urethra. The use of polypropylene mesh in urogynaecology, including mid-urethral slings, is restricted in many countries. This is a review update (previous search date 2012).
OBJECTIVES
To assess the effects of single-incision sling operations for treating urinary incontinence in women, and to summarise the principal findings of relevant economic evaluations.
SEARCH METHODS
We searched the Cochrane Incontinence Specialised Register, which contains trials identified from: CENTRAL, MEDLINE, MEDLINE In-Process, MEDLINE Epub Ahead of Print, and two trials registers. We handsearched journals, conference proceedings, and reference lists of relevant articles to 20 September 2022.
SELECTION CRITERIA
We included randomised or quasi-randomised controlled trials in women with stress (or stress-predominant mixed) urinary incontinence in which at least one, but not all, trial arms included a single-incision sling.
DATA COLLECTION AND ANALYSIS
We used standard Cochrane methodological procedures. The primary outcome was subjective cure or improvement of urinary incontinence.
MAIN RESULTS
We included 62 studies with a total of 8051 women in this review. We did not identify any studies comparing single-incision slings to no treatment, conservative treatment, colposuspension, or laparoscopic procedures. We assessed most studies as being at low or unclear risk of bias, with five studies at high risk of bias for outcome assessment. Sixteen trials used TVT-Secur, a single-incision sling withdrawn from the market in 2013. The primary analysis in this review excludes trials using TVT-Secur. We report separate analyses for these trials, which did not substantially alter the effect estimates. We identified two cost-effectiveness analyses and one cost-minimisation analysis. Single-incision sling versus autologous fascial sling One study (70 women) compared single-incision slings to autologous fascial slings. It is uncertain if single-incision slings have any effect on risk of dyspareunia (painful sex) or mesh exposure, extrusion or erosion compared with autologous fascial slings. Subjective cure or improvement of urinary incontinence at 12 months, patient-reported pain at 24 months or longer, number of women with urinary retention, quality of life at 12 months and the number of women requiring repeat continence surgery or sling revision were not reported for this comparison. Single-incision sling versus retropubic sling Ten studies compared single-incision slings to retropubic slings. There may be little to no difference between single-incision slings and retropubic slings in subjective cure or improvement of incontinence at 12 months (risk ratio (RR) 0.99, 95% confidence interval (CI) 0.91 to 1.07; 2 trials, 297 women; low-certainty evidence). It is uncertain whether single-incision slings increase the risk of mesh exposure, extrusion or erosion compared with retropubic minimally-invasive slings; the wide confidence interval is consistent with both benefit and harm (RR 1.55, 95% CI 0.24 to 9.82; 3 trials, 267 women; low-certainty evidence). It is uncertain whether single-incision slings lead to fewer women having postoperative urinary retention compared with retropubic slings; the wide confidence interval is consistent with possible benefit and harm (RR 0.47, 95% CI 0.12 to 1.84; 2 trials, 209 women; low-certainty evidence). The effect of single-incision slings on the risk of repeat continence surgery or mesh revision compared with retropubic slings is uncertain (RR 4.19, 95% CI 0.31 to 57.28; 2 trials, 182 women; very low-certainty evidence). One study reported quality of life, but not in a suitable format for analysis. Patient-reported pain at more than 24 months and the number of women with dyspareunia were not reported for this comparison. We downgraded the evidence due to concerns about risks of bias, imprecision and inconsistency. Single-incision sling versus transobturator sling Fifty-one studies compared single-incision slings to transobturator slings. The evidence ranged from high to low certainty. There is no evidence of a difference in subjective cure or improvement of incontinence at 12 months when comparing single-incision slings with transobturator slings (RR 1.00, 95% CI 0.97 to 1.03; 17 trials, 2359 women; high-certainty evidence). Single-incision slings probably have a reduced risk of patient-reported pain at 24 months post-surgery compared with transobturator slings (RR 0.12, 95% CI 0.02 to 0.68; 2 trials, 250 women; moderate-certainty evidence). The effect of single-incision slings on the risk of dyspareunia is uncertain compared with transobturator slings, as the wide confidence interval is consistent with possible benefit and possible harm (RR 0.78, 95% CI 0.41 to 1.48; 8 trials, 810 women; moderate-certainty evidence). There are a similar number of mesh exposures, extrusions or erosions with single-incision slings compared with transobturator slings (RR 0.61, 95% CI 0.39 to 0.96; 16 trials, 2378 women; high-certainty evidence). Single-incision slings probably result in similar or reduced cases of postoperative urinary retention compared with transobturator slings (RR 0.68, 95% CI 0.47 to 0.97; 23 trials, 2891 women; moderate-certainty evidence). Women with single-incision slings may have lower quality of life at 12 months compared to transobturator slings (standardised mean difference (SMD) 0.24, 95% CI 0.09 to 0.39; 8 trials, 698 women; low-certainty evidence). It is unclear whether single-incision slings lead to slightly more women requiring repeat continence surgery or mesh revision compared with transobturator slings (95% CI consistent with possible benefit and harm; RR 1.42, 95% CI 0.94 to 2.16; 13 trials, 1460 women; low-certainty evidence). We downgraded the evidence due to indirectness, imprecision and risks of bias.
AUTHORS' CONCLUSIONS
Single-incision sling operations have been extensively researched in randomised controlled trials. They may be as effective as retropubic slings and are as effective as transobturator slings for subjective cure or improvement of stress urinary incontinence at 12 months. It is uncertain if single-incision slings lead to better or worse rates of subjective cure or improvement compared with autologous fascial slings. There are still uncertainties regarding adverse events and longer-term outcomes. Therefore, longer-term data are needed to clarify the safety and long-term effectiveness of single-incision slings compared to other mid-urethral slings.
Identifiants
pubmed: 37888839
doi: 10.1002/14651858.CD008709.pub4
pmc: PMC10604512
doi:
Banques de données
ClinicalTrials.gov
['NCT00534365', 'NCT00843908', 'NCT01095159', 'NCT00676273', 'NCT02506309', 'NCT00527696', 'NCT02540525', 'NCT01230450', 'NCT02599051', 'NCT01054833', 'NCT01384084', 'NCT02867748', 'NCT03052985', 'NCT01348334', 'NCT00751088', 'NCT03520114', 'NCT04586166', 'NCT01799122', 'NCT02263534', 'NCT03515109', 'NCT03916471', 'NCT05225168']
Types de publication
Systematic Review
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
CD008709Commentaires et corrections
Type : UpdateOf
Informations de copyright
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Références
Int Urogynecol J. 2014 Oct;25(10):1343-8
pubmed: 24643378
Urology. 2013 Sep;82(3):552-9
pubmed: 23845666
Ceska Gynekol. 2012 Aug;77(4):350-7
pubmed: 23094777
Ceska Gynekol. 2012 Oct;77(5):403-7
pubmed: 23116343
Int Urogynecol J. 2018 Sep;29(9):1387-1395
pubmed: 29549394
Am J Obstet Gynecol. 2014 Aug;211(2):171.e1-7
pubmed: 24631433
Urologiia. 2011 Jul-Aug;(4):16-20
pubmed: 22066235
Int Urogynecol J. 2019 Jul;30(7):1045-1059
pubmed: 30715575
Int Urogynecol J. 2017 Jul;28(7):1077-1084
pubmed: 28025686
World J Clin Cases. 2020 Sep 26;8(18):4043-4050
pubmed: 33024761
Female Pelvic Med Reconstr Surg. 2015 May-Jun;21(3):154-9
pubmed: 25730435
J Invest Surg. 2020 Mar;33(3):203-210
pubmed: 30461324
Eur Urol. 2010 Jun;57(6):973-9
pubmed: 20206437
N Engl J Med. 2022 Mar 31;386(13):1230-1243
pubmed: 35353961
Int Urogynecol J. 2013 Dec;24(12):2059-64
pubmed: 23712578
BMC Urol. 2018 May 18;18(1):44
pubmed: 29776405
Cochrane Database Syst Rev. 2017 Jul 31;7:CD001755
pubmed: 28759116
Cochrane Database Syst Rev. 2017 Jul 25;7:CD002912
pubmed: 28741303
Int Urogynecol J. 2021 Jan;32(1):141-148
pubmed: 32583011
BJU Int. 2019 Apr;123(4):566-584
pubmed: 29927049
Cochrane Database Syst Rev. 2017 Jul 31;7:CD006375
pubmed: 28756647
Eur J Obstet Gynecol Reprod Biol. 2012 Nov;165(1):115-21
pubmed: 22917936
Eur J Obstet Gynecol Reprod Biol. 2015 Feb;185:151-5
pubmed: 25589424
Medicine (Baltimore). 2018 Apr;97(14):e0283
pubmed: 29620645
Health Technol Assess. 2019 Mar;23(14):1-306
pubmed: 30929658
Int Urogynecol J. 2020 Apr;31(4):703-710
pubmed: 31410518
Int Urogynecol J. 2017 Jul;28(7):1041-1047
pubmed: 27921162
Neurourol Urodyn. 2022 Sep;41(7):1601-1611
pubmed: 35842824
Cochrane Database Syst Rev. 2014 Jun 01;(6):CD008709
pubmed: 24880654
Eur J Obstet Gynecol Reprod Biol. 2012 Jul;163(1):108-12
pubmed: 22552180
Int Urogynecol J. 2011 Nov;22(11):1369-74
pubmed: 21567258
J Minim Invasive Gynecol. 2014 Mar-Apr;21(2):303-10
pubmed: 24148568
Int Urogynecol J. 2016 Oct;27(10):1497-505
pubmed: 27037563
Neurourol Urodyn. 2017 Apr;36(4):1187-1193
pubmed: 27564322
Eur Urol. 2016 Jul;70(1):148-158
pubmed: 26874810
Prague Med Rep. 2015;116(3):210-8
pubmed: 26445392
Int Urogynecol J. 2012 Sep;23(9):1293-9
pubmed: 22527555
Menopause. 2014 Jun;21(6):641-5
pubmed: 24149923
Int Urogynecol J. 2020 Sep;31(9):1925-1931
pubmed: 31784809
Acta Obstet Gynecol Scand. 2017 Nov;96(11):1347-1356
pubmed: 28815547
Eur J Obstet Gynecol Reprod Biol. 2015 Dec;195:117-121
pubmed: 26519819
Eur Urol. 2014 Jun;65(6):1211-7
pubmed: 24486308
Biomed Res Int. 2013;2013:139813
pubmed: 24151581
Neurourol Urodyn. 2019 Sep;38(7):1852-1858
pubmed: 31236976
Int Urogynecol J. 2013 Aug;24(8):1265-9
pubmed: 23563892
Female Pelvic Med Reconstr Surg. 2012 Jan-Feb;18(1):41-5
pubmed: 22453267
Ceska Gynekol. 2011 Oct;76(5):349-55
pubmed: 22132634
Int Urogynecol J. 2016 May;27(5):791-6
pubmed: 26630947
Eur J Obstet Gynecol Reprod Biol. 2018 Nov;230:141-146
pubmed: 30286363
World J Urol. 2018 Mar;36(3):459-465
pubmed: 29299661
BJOG. 2007 May;114(5):522-31
pubmed: 17362484
BJU Int. 2013 Dec;112(8):1169-77
pubmed: 24053310
Ceska Gynekol. 2008 Oct;73(5):271-7
pubmed: 19110953
Int Urogynecol J. 2010 Jul;21(7):787-93
pubmed: 20186388
Int Urogynecol J. 2013 Feb;24(2):223-9
pubmed: 22707006
Int Urogynecol J. 2014 Oct;25(10):1333-41
pubmed: 24737301
Int Urogynecol J. 2020 Aug;31(8):1545-1550
pubmed: 31776620
Urologia. 2019 Aug;86(3):152-155
pubmed: 31072274
J Minim Invasive Gynecol. 2013 Mar-Apr;20(2):198-204
pubmed: 23352582
J Urol. 2011 Apr;185(4):1356-62
pubmed: 21334682
Int J Gynaecol Obstet. 2010 Dec;111(3):233-6
pubmed: 20822770
Eur Urol. 2011 Jun;59(6):940-4
pubmed: 21277076
Int Urogynecol J. 2018 Jan;29(1):37-44
pubmed: 28577171
BJOG. 2010 May;117(6):730-5
pubmed: 20175874
Low Urin Tract Symptoms. 2015 Jan;7(1):9-16
pubmed: 26663645
Int Urogynecol J. 2014 Jul;25(7):909-14
pubmed: 24452619
Maturitas. 2005 Nov 30;52 Suppl 2:S35-47
pubmed: 16297577
Int Urogynecol J. 2016 Jun;27(6):871-7
pubmed: 26670576
Int Urogynecol J. 2011 Feb;22(2):145-56
pubmed: 20857087
Ceska Gynekol. 2015 Jun;80(3):196-203
pubmed: 26087214
Int J Gynaecol Obstet. 2011 May;113(2):108-11
pubmed: 21338986
Neurourol Urodyn. 2018 Sep;37(7):2184-2190
pubmed: 30088679
Cochrane Database Syst Rev. 2019 Oct 3;10:ED000142
pubmed: 31643080
BMC Urol. 2020 May 6;20(1):51
pubmed: 32375733
Int Urogynecol J. 2013 Sep;24(9):1459-65
pubmed: 23208003
Int Urogynecol J. 2017 Mar;28(3):461-467
pubmed: 27714435
Curr Urol Rep. 2011 Oct;12(5):358-62
pubmed: 21847532
Obstet Gynecol. 2015 Jan;125(1):27-34
pubmed: 25560100
Arch Gynecol Obstet. 2018 Jun;297(6):1483-1493
pubmed: 29556707
Urology. 2019 Nov;133:91-95
pubmed: 31415780
Korean J Urol. 2010 Apr;51(4):250-6
pubmed: 20428427
Int Urogynecol J. 2010 Oct;21(10):1211-7
pubmed: 20502877
Maturitas. 2016 Dec;94:52-57
pubmed: 27823745
J Obstet Gynaecol Res. 2015 Jan;41(1):127-31
pubmed: 25363659
Arch Gynecol Obstet. 2016 Feb;293(2):457-63
pubmed: 26573010
BMC Res Notes. 2014 Dec 22;7:941
pubmed: 25532604
Int Urogynecol J. 2012 Oct;23(10):1403-12
pubmed: 22314891
Obstet Gynecol. 2001 Sep;98(3):398-406
pubmed: 11530119
Ceska Gynekol. 2016 Fall;81(5):324-335
pubmed: 27897018
Value Health. 2014 Nov;17(7):A509
pubmed: 27201564
Cochrane Database Syst Rev. 2017 Jul 25;7:CD003881
pubmed: 28738443
Eur Urol. 2014 Dec;66(6):1179-85
pubmed: 25168619
Am J Obstet Gynecol. 2015 Jul;213(1):35.e1-35.e9
pubmed: 25637849
Int Urogynecol J. 2015 Feb;26(2):213-8
pubmed: 25030327
Cochrane Database Syst Rev. 2017 Jul 26;7:CD008709
pubmed: 28746980
Int Urogynecol J. 2019 Dec;30(12):2171-2175
pubmed: 30944936
Eur Urol. 2011 Sep;60(3):468-80
pubmed: 21621321
Obstet Gynecol Clin North Am. 2021 Sep;48(3):449-466
pubmed: 34416931
Int Urogynecol J. 2011 Jul;22(7):827-33
pubmed: 21365331
BMJ Open. 2017 Aug 11;7(8):e015111
pubmed: 28801396
Obstet Gynecol. 2014 Mar;123(3):553-561
pubmed: 24499750
BJOG. 2003 Mar;110(3):255-62
pubmed: 12628263
Cochrane Database Syst Rev. 2019 Dec 10;12:CD002239
pubmed: 31821550
Obstet Gynecol. 2012 Feb;119(2 Pt 1):328-37
pubmed: 22270285
Urogynecology (Phila). 2023 Feb 1;29(2):113-120
pubmed: 36735422
J Urol. 2012 Jul;188(1):194-9
pubmed: 22591959
Eur J Obstet Gynecol Reprod Biol. 2013 Oct;170(2):563-6
pubmed: 23972452
J Obstet Gynaecol Res. 2016 Dec;42(12):1773-1781
pubmed: 27718284
BJU Int. 2011 Sep;108(5):652-7
pubmed: 21756280
J Womens Health (Larchmt). 2016 Apr;25(4):355-9
pubmed: 26886509
Cochrane Database Syst Rev. 2020 Jan 28;1:CD001754
pubmed: 31990055
Int Urogynecol J. 2011 Jul;22(7):781-7
pubmed: 21499755
Eur Urol. 2014 Feb;65(2):402-27
pubmed: 24055431